Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 77

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 77
---
Through LipoVation,
our operating subsidiary which we acquired in July 2024, we are building on proven science to tackle some of the toughest challenges
in medicine—infectious diseases and cancer. Our approach is inspired by the success of a well-known cancer drug called doxorubicin,
which was the first FDA-approved treatment to use nanotechnology for drug delivery.

We use tiny, specially designed fat-based
particles called liposomes to carry powerful medicines directly to where they’re needed in the body. This method is one of the
most advanced ways to deliver medicine and allows the drugs to stay in the bloodstream longer, reach their target more precisely, and
release their effects in a controlled way. This approach leads to treatments that are more effective and have a reduced risk of side
effects. At Revium Rx, we're leveraging these features to concentrate our treatments in diseased tissues, such as tumors and infected
areas, while avoiding healthy cells.

We are developing a portfolio of Nano-Liposomal
Particle NLP-based pharmaceutical candidates and plan to complete the development and commercialization of a series of medical technologies
including:

| ● | A                                                                                                   
 nanoparticle-based formulation of a well-known, potent antibiotic limited to topical use            
 due to its instability in blood when administered systemically. The novel formulation, Mupirocin,   
 supported by in vitro and in vivo animal studies, demonstrated promising potential in combating     
 severe, life-threatening infections caused by antibiotic-resistant bacteria including among         
 others Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci         
 (VRE), and Neisseria gonorrhoeae.   If approved, the novel proprietary formulation                  
 of nano-mupirocin will be administered systemically, providing extended presence in the bloodstream 
 and enhanced delivery of mupirocin to inflamed areas of the body.                                   |

| ● | A novel combination therapy designed to                                                                                                          
 enhance the efficacy of existing cancer treatments.: a nanoparticles-based formulation of angiotensin receptor blockers (ARB) for                
 intravenous administration being developed to significantly improve existing anticancer treatment outcomes.                                      |
| ● | In addition, as discussed                                                                                                                        
 further below, subject to the completion and our review of an animal study currently being performed in Israel under the auspices                
 of Prof. Yehezkel Barenholz at the Hebrew University of Jerusalem, we may continue with the development of Liposomal Protein-Loaded              
 Technology (LPLT